Already have an account? Sign in.
Big Boost for Ocular Therapeutix Stock and Drug Forecast
Piper Sandler raised Ocular Therapeutix stock target to $31 and boosted the AXPAXLI sales forecast to $3.2B due to promising eye drug trial data.
Piper Sandler raised Ocular Therapeutix stock target to $31 and boosted the AXPAXLI sales forecast to $3.2B due to promising eye drug trial data.
SpaceX’s Starship upper stage returned from a 22-hour orbital mission and was caught by the launch tower for the first time, marking a key reusability milestone.
The Financial Times reports Amazon is the hyperscaler behind Fermi America’s new 600 MW power deals following the breakdown of 2025 talks.
Meta’s internal prediction market app Takes lets employees bet with credibility points instead of cash. Launch plans remain unclear.
Be the first to know when deals break, stocks move, or biotech headlines hit.